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Abstract
Background: In light of the increased risk of progressive multifocal encephalopathy (PML) development under
long-term treatment with the monoclonal antibody natalizumab which is approved for treatment of active relapsing
remitting multiple sclerosis (RRMS), there is a clear need for alternative treatment options with comparable efficacy
and reduced PML risk. One such option is fingolimod, a functional sphingosin-1-receptor antagonist that has
been approved as first oral drug for treatment of active RRMS. However, the optimal switching design in terms of
prevention of disease reoccurrence is still unknown. Moreover, potential additive effects of both drugs on immune
functions, especially with regard to migration, have not yet been evaluated.
Methods/design: This is an exploratory, open-label, monocentric, investigator-initiated clinical trial. Fifteen
RRMS patients under stable treatment with natalizumab will receive one last natalizumab infusion followed by a
wash-out period of 8 weeks before fingolimod treatment initiation for a period of 24 weeks. Disease activity under
natalizumab and during switching will be closely monitored by assessment of relapse rate and disease severity as
well as high-frequent high-resolution magnetic resonance imaging including quantitative diffusion tensor imaging.
Immunological assays include longitudinal assessment of adhesion molecule expression, functional evaluation of
the migratory capacity of immune cells in an in-vitro model of the blood–brain-barrier, and the quality of cellular
antiviral immune responses.
Discussion: Our trial represents the first detailed and longitudinal functional analysis of key immunological
parameters in the process of switching from natalizumab and fingolimod, especially with regard to potential
additive effects of both drugs on trafficking and immune surveillance. Moreover, our study will generate valuable
information about even subtle disease exacerbations as consequence of natalizumab cessation, which will help
to understand whether a switching protocol containing a wash-out period of 8 weeks before fingolimod treatment
is appropriate in terms of disease stability.
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Background
Multiple sclerosis is a chronic autoimmune disease of
the central nervous system (CNS) characterized by inva-
sion of inflammatory immune cells into the CNS accom-
panied by destruction of myelin and axons [1]. In most
cases, the disease initially takes a relapsing-remitting
course with acute relapses followed by complete or par-
tial recovery. This relapsing-remitting disease course is
particularly responsive towards currently available im-
munomodulatory therapies [1].
One such compound is natalizumab, a recombinant
humanized monoclonal antibody that binds to the α4-
subunit of α4β1 and α4β7 integrins [2]. Natalizumab
effectively interferes with immune cell transmigration
across the endothelial cell layer at the blood–brain-barrier
(BBB) [3]. This mechanism of action has proven very suc-
cessful, as clinical studies documented a profound reduc-
tion in the annual relapse rate of 68 % and a 42 %
reduction in disability progression compared to placebo
[2]. However, long-term application of natalizumab has
been limited by a rare but serious complication, i.e. pro-
gressive multifocal leucoencephalopathy (PML), an oppor-
tunistic brain infection caused by JC virus reactivation.
The underlying mechanism of natalizumab-associated
PML is still unknown, but it has been demonstrated that
disease incidence increases with treatment duration: For
JCV positive individuals (50-60 % of the general popula-
tion) after 2 years of therapy, risk increases to 1:400, which
is further increasing to ≈ 1:100 in case of previous im-
munosuppressive therapy [4, 5]. Hence, this indicates that
high efficacy correlates with compromised immune sur-
veillance and increased PML risk.
In the last years, new assays have been developed to
improve PML risk estimation during natalizumab treat-
ment [6, 7], but so far, it is still challenging to safely
identify pre-PML-cases and prevent disease onset by
prompt treatment interruption and natalizumab elimin-
ation procedures. Therefore, with increasing PML risk in-
dividual future treatment options have to be re-considered
and hence a proportion of patients will opt to discontinue
natalizumab treatment. However, several studies docu-
mented a profound increase in disease activity upon nata-
lizumab discontinuation. In these patients, clinical and
MRI disease activity remained low for the first 3 months
and increased by the 4th month following dose cessation
[8–10]. This particular temporal pattern suggests that re-
currence of disease activity follows pharamacokinetics of
natalizumab elimination and receptor saturation [11, 12].
The time-course of reconstitution of immune func-
tions upon natalizumab cessation however is completely
unclear, and hence, a sound recommendation with re-
gard to a normalized PML risk after treatment discon-
tinuation cannot be given based on the data available so
far. Although a direct link to the increased PML risk has
to be proven, a study by Stüve and colleagues demon-
strated an altered CD4+/CD8+ T-cell ratio in the cere-
brospinal fluid (CSF) of natalizumab patients, which was
normalized after 6 months of treatment cessation [13].
Moreover, data from our group suggest that certain im-
mune functions especially with regard to the migratory
activity of immune cells might be fundamentally altered
under long-term natalizumab treatment as for example
reflected by increased PSGL-1 expression [14], suggest-
ing that a short wash-out period might not be sufficient
for regaining full immune competence.
For patients that had been treated with natalizumab,
disease-modifying treatment has to be re-initiated to
prevent disease exacerbation. Due to the fact that natali-
zumab is approved for patients who did not respond
properly to first-line therapies such as Interferon-beta
(IFNβ) or glatirameracetate (GA) or exhibited high pre-
treatment disease activity, there is a clear need to con-
tinue treatment with an appropriate immunomodulatory
agent such as fingolimod.
Fingolimod (FTY720) - Gilenya® is an oral immuno-
modulatory drug that serves as a functional antagonist
of the sphinosine-1-phosphate (S1P) receptor family
resulting in lymphocyte sequestration within lymph nodes
[15, 16]. In two large clinical studies (TRANSFORMS and
FREEDOMS), fingolimod showed a significant reduction
of the annual relapse rate compared to either placebo or
the active comparator IFNβ-1a and also significantly im-
proved MRI findings [17, 18]. Mechanistically, immune
cell sequestration predominantly affects central memory
T-cells (TCM) and naïve T-cells (Tn), whereas effector
memory T-cells (TEM), which are critically involved in
immune surveillance are relatively spared [19]. It is not
clear whether these differential effects on immune cell
trafficking might also impair effective antiviral immunity
during systemic infections, either against newly acquired
or persisting latent viruses. In the clinical studies, two fatal
cases of herpes-virus infections occurred under fingoli-
mod treatment, and hence, sufficient immunity against
varizella-zoster-virus (VZV) has to be documented before
fingolimod treatment initiation. One study by Ricklin
et al. observed an increased incidence of latent VZV
reactivation in saliva of fingolimod-treated MS patients
[20]. In a recent analysis of post-marketing data, an
increased incidence of VZV-reactivation compared to
other immune-modulatory drugs has been described,
however, an increased incidence of severe or atypical
herpes virus infections has not been observed [21]. So
far, only one case of natalizumab-independent PML has
been described under fingolimod; however, several PML-
cases occurred after switching from natalizumab to fingo-
limod and were regarded as “carry-over-PML”[22–24].
Due to the fact that both drugs interfere with immune
cell trafficking albeit via different mechanisms, it is
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crucial to understand the distinct effects of these drugs
on immune cell trafficking and immune reconstitution
in the clinical relevant situation of switching immune-
modulatory treatment from natalizumab to fingolimod.
The goal of our open, prospective, monocentric trial in
patients with RRMS is therefore to improve our under-
standing of drug-induced changes in immune cell migra-
tion and immune cell function and its consequences on
anti-viral immunity and to monitor its impact on clinical
and paraclinical disease activity in RRMS patients where




ToFingo-successor is a 32-week, open, monocentric,
prospective, exploratory, single-arm study that is con-
ducted at the Department of Neurology, University
hospital Münster. Recruitment has been started in April
2014. Fifteen patients with RRMS (according to the 2010
revised McDonald criteria) [25], who are currently treated
with natalizumab for at least 12 months and where treat-
ment discontinuation is considered for at least one of the
following reasons can be included in this study: treatment
duration for more than 2 years, positive JCV antibody sta-
tus, adverse effects including hypersensitivity reactions,
presence of anti-natalizumab neutralizing antibodies, or
any other valid medical reason. One last natalizumab infu-
sion is part of the trial followed by a wash-out period of
8 weeks before treatment initiation with fingolimod. Dur-
ing the study, patients are regularly monitored by clinical
and MRI assessments to detect early signs of disease re-
activation. Blood sampling to collect peripheral immune
cells for subsequent immunological assessments is done
every 4 weeks, moreover, sequential CSF analysis is an
optional part of the study protocol.
The study is approved by the local ethics committee
and the German competent authority (Federal Institute
for Drugs and Medical Devices). The trial is registered
at Clinicaltrials.gov (NCT02325440) and will be con-
ducted in accordance with the Declaration of Helsinki
and the guidelines of the International Conference on
Harmonization of Good Clinical Practice (ICH-GCP) as
well as the applicable German laws. All participants will
be required to give written informed consent. Monitor-
ing will be performed according to ICH-GCP.
Participants
The inclusion criteria for participation included diagno-
sis of definite RRMS according to the revised 2010
McDonald criteria [25], an age of 18 to 65 years, a score
of 0–6.0 on the expanded disability status scale (EDSS)
[26], and current immunomodulatory treatment with
natalizumab for at least 12 months where treatment
discontinuation is considered for at least one of the fol-
lowing reasons: treatment duration for more than 2 years,
positive JCV antibody status, adverse effects including
hypersensitivity reactions, presence of anti-natalizumab
neutralizing antibodies, or any other valid medical reason
(Table 1).
The main exclusion criteria include any disease course
other than RRMS, recent immunosuppressive treatment,
a history of malignancy (except cutaneous basal cell car-
cinoma), severe active infections, patients negative for
VZV IgG antibodies prior to baseline, medical conditions
prohibiting treatment with fingolimod (such as severe dia-
betes mellitus, relevant cardiovascular conditions, severe
respiratory disease or severe hepatic injury), relevant white
blood cell abnormalities, patients unable to undergo MRI
scans, and pregnant or lactating women. The full list of
exclusion criteria is depicted in Table 1.
Interventions
Patients’ eligibility will be determined during screening.
At the baseline visit, patients will receive their last nata-
lizumab infusion. Optionally, CSF analysis will be per-
formed at this time point to detect natalizumab-induced
changes in immune cell subset composition in the CSF.
MRI imaging will be performed to determine disease
activity under natalizumab treatment and to screen for
possible PML-induced changes. During the defined
8 week wash-out phase, patients will be clinically moni-
tored every 4 weeks. After wash-out, fingolimod treat-
ment will be started and visits will be carried out every
4 weeks for the next 24 weeks of fingolimod treatment.
MRI scans will be performed at the time of fingolimod
initiation and at weeks 4, 8, 16, and 20 after treatment
initiation, respectively. Optionally, a second CSF analysis
will be performed 24 weeks after initiation of fingolimod
treatment. Optional follow-up visits will be offered at
week 28 and week 32 after fingolimod treatment initi-
ation. Blood sampling for subsequent immunological
analyses will be performed at each visit. If necessary, un-
scheduled visits can be performed at any time. Table 2
illustrates the timeline of all interventions. An overview
of the immunological asays is provided in Table 3.
Outcome parameters
Primary endpoints
The co-primary endpoints are to investigate the effect of
switching therapy from natalizumab to fingolimod on
peripheral blood immune cells regarding 1) CD49d ex-
pression over time and 2) changes in their migratory
capacity in an in-vitro model of the BBB. It has been
demonstrated that natalizumab causes an early and pro-
nounced reduction in T-lymphocyte CD49d expression
[14] accompanied by an impaired transendothelial mi-
gratory capacity [27]. CD49d expression was shown to
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Table 1 Eligibility criteria
Inclusion criteria Written informed consent provided
Male and female subjects aged 18 to 65 years
Diagnosis of RRMS, defined by revised McDonald criteria (2010)
Expanded Disability Status Scale (EDSS) at screening score≤ 6.0
Treatment with natalizumab for at least 12 months prior to screening and consideration of treatment discontinuation
for any of the following reasons:
• treatment duration > 2 years
• positive JCV antibody status
• adverse effects including hypersensitivity reactions
• presence of anti-natalizumab neutralizing antibodies
• any other valid medical reason
Exclusion criteria History of chronic disease of the immune system other than MS, which requires systemic immunosuppressive treatment,
or a known immunodeficiency syndrome.
Diagnosis of Crohn’s disease or ulcerative colitis
Treatment with:
• systemic corticosteroids or immunoglobulins within 1 month prior to baseline
• immunosuppressive medications such as azathioprine, cyclophosphamide or methotrexate within 3 months prior to baseline
• monoclonal antibodies (excluding natalizumab) within 3 months prior to baseline.
• cladribine or mitoxantrone at any time.
History of malignancy of any organ system (other than cutaneous basal cell carcinoma)
Uncontrolled diabetes mellitus (HbA1c >7 %)
Diagnosis of macular edema during Screening Phase
Severe active infections, active chronic infection.
Negative for varicella-zoster virus IgG antibodies prior to baseline.
Vaccination with live or live-attenuated vaccine (including varicellazoster virus or measles) within 1 month prior to baseline
Previous therapy with total lymphoid irradiation or bone marrow transplantation
Any medically unstable condition, as assessed by the investigator
Any of the following cardiovascular conditions and/or findings in the screening ECG:
• history of cardiac arrest
• myocardial infarction within the past 6 months prior to screening or with current unstable ischemic heart disease
• history of angina pectoris due to coronary spasm
• heart failure (NYHA III-IV) or any severe cardiac disease as determined by the investigator
• history or presence of a second-degree AV block, Type II or a third-degree AV block or QTc interval > 450 ms in males
and > 470 ms in females
• treatment with Class Ia (ajmaline, disopyramide, procainamide, quinidine) or Class III antiarrhythmic drugs (e.g.,
amiodarone, bretylium, sotalol, ibulitide, azimilide, dofelitide)
• proven history of sick sinus syndrome or sino-atrial heart block
• uncontrolled hypertension
• Resting HR lower than 45 bpm
Presence of severe respiratory disease, pulmonary fibrosis or chronic obstructive pulmonary disease (Class III-IV)
Any of the following hepatic conditions:
• severe hepatic injury (Child-Pugh class C)
• total bilirubin greater than 2 times the upper limit of the normal range
• AST or ALT greater than 2 times the upper limit of the normal range
• alkaline phosphatase (AP) greater than 2 times the upper limit of the normal range
White blood cell (WBC) count <3,500/mm3 or
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be an indicator for an appropriate biological response to
natalizumab treatment [28], and wash-out of Natalizu-
mab by plasma exchange restores the transendothelial
migratory capacity of lymphocytes [29]. Furthermore,
CD62L expression is reduced by Natalizumb therapy per
se and a strong reduction in CD62L is associated with
increased risk of developing PML [6]. We therefore aim
to assess changes in these molecules over time in the
course of switching.
PBMC isolation and cryo-preservation For all im-
munological assays using peripheral immune cells, per-
ipheral venous blood (90 ml EDTA blood) will be
obtained from all subjects included in this study at dif-
ferent time points as indicated above. PBMCs will be
isolated from the blood via density gradient centrifuga-
tion as described before [30]. Purified PBMC will be ali-
quoted and cryo-preserved in liquid nitrogen for at least
4 weeks before analysis. After thawing, the CD49d and
CD62L expression on CD4+ and CD8+ T cells will be
evaluated via flow cytometry using a Navios™ flow cyt-
ometer (Beckmann Coulter, Krefeld, Germany).
Transmigration assay To assess the migratory capacity
of immune cells across the BBB a transmigration assay
will be used as described by our group [14]: A defined
number of PBMC will be added on top of a confluent
monolayer of primary human brain endothelial cells
seeded on transwells with a pore size of 3.0 μm and left
to migrate for 6 h at 37 °C into a medium-filled chamber
below. Migrated immune cells will be characterized and
quantified via flow cytometry. By correlating cell counts
and composition of immune-cell populations before and
after the transmigration, potential changes in the migra-
tory capacity of each immune-cell type throughout the
study will be evaluated.
Secondary endpoints The secondary endpoints com-
prise changes in paraclinical disease activity over time
upon natalizumab cessation and switching to fingolimod
treatment. MRI disease activity is defined as change in
T2w lesion load, detection of Gd + lesions as well as
changes in T1w and FLAIR lesions compared to the
baseline MRI.
MRI acquisitions will be performed with a 3 T MRI
scanner (TIM Trio, Siemens AG, Erlangen, Germany) and
a 12-channel (matrix) head coil (Siemens AG, Erlangen,
Germany). Images of the following MRI sequences will be
obtained: a native isotropic 3D MPRAGE T1-weighted se-
quence; diffusion-weighted echo planar imaging for (DTI);
axial turbo spin-echo (TSE) FLAIR; sagittal TSE FLAIR;
3D MPRAGE T1-weighted after intravenous gadolinium-
DTPA (diethylene triamine penta-acetic acid) 0.1 mmol/
kg injection; axial PD/T2-weighted TSE.
Exploratory endpoints In addition, several exploratory
endpoints have been defined. Exploratory immunological
objectives comprise the analysis of the functionality of
virus-specific T-cell responses and of changes in immune
cell subset composition in the course of our study.
Additionally, quantitative DTI imaging will be per-
formed throughout the study in order to search for
radiological signs of disease exacerbation that escape
detection by conventional radiological methods.
Finally, clinical parameters monitored throughout the
whole study shall be correlated with radiological and im-
munological parameters.
Assessment of anti-viral immune responses To assess
the quality of virus-specific cellular responses of CD4+
and CD8+ cells throughout the study and in comparison
with immune cells derived from healthy controls and
treatment-naïve RRMS patients an established protocol
will be followed [31, 32]. In detail, thawed PBMC will be
Table 1 Eligibility criteria (Continued)
lymphocyte count <800/mm3 at screening
Any of the following neurologic/psychiatric disorders:
• history of substance abuse (drug or alcohol) in the past five years or any other factor (i.e., serious psychiatric condition)
that may interfere with the subject’s ability to cooperate and comply with the study procedures
• progressive neurological disorder, other than MS, which may affect participation in the study
Incapability to undergo MRI scans, including claustrophobia or history of hypersensitivity to gadolinium-DTPA
Treatment with investigational drug or therapy within 180 days or 5 half-lives before baseline, whichever is longer
Pregnancy or breast feeding (lactating), confirmed by a positive hCG laboratory
Child-bearing potential (Unless the women concerned are using effective contraception during the study and for 5
half-lives after stopping treatment. In case of use of oral contraception women should have been stable on the same
medication for a minimum of 3 months before baseline)
History of hypersensitivity to the study drugs or to drugs of similar chemical classes
Prior participation in a trial with fingolimod
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restimulated with VZV antigen. After 5 h at 37 °C, VZV-
specific production of TNFa, IFNg and IL-2 by CD4+
and CD8+ memory T cells will be measured via intracellu-
lar flow cytometry. This analysis will reveal whether treat-
ment with natalizumab itself or switching to fingolimod
might affect cellular immune responses against herpes
viruses.
Immune cell phenotyping Changes in immune-cell
subset composition and immune-cell phenotype will be
Table 2 Schedule of regular study visits
Study Phase Screening Wash-out ← Treatment → Follow up
Visit* 1 2 3 4 5 6 7 8 9 10** 11 12
Study Week −4 – 0 0 4 8 12 16 20 24 28 32 36 40
Obtain informed consent X
Background/Demography X
Inclusion/exclusion criteria X X
Medical History X
MS history/MS treatment X
Prior/Concomitant medication X X X X X X X X X X X X
Pregnancy test (serum) X
Pregnancy test (urine dipstick) X X X X X X X X X X X
Physical examination X X X X X X X X X X
MSFC X6 X X
Neurological examination (including EDSS) X X X X X X X X X X
Vital signs X X X X X X X X X X X X
Clinical laboratory (blood chemistry/hematology) X X X X X X X X X X X X
PBMC isolation for evaluation of immunological
parameters
X X X X X X X X X X X
CSF sampling1 X X
JCV sample X X
Ophtalmologic examination2 X X
Last natalizumab dose X
ECG X
First dose monitoring (=FDM)3 X
Dispensing of patient’s diary X
Collecting of patient’s diary X
Study drug prescription X X X
MRI (including DTI)4,5 X X X X X X
MS relapse X X X X X X X X X X X X
Adverse events/SAEs X X X X X X X X X X X
*At each visit the patient must be reminded of the importance of remaining vigilant for infections, performing regular skin selfassessments, and in women of
child bearing age, practicing contraception per protocol
** EOT/ Assessments also for PPW (Premature Patient Withdrawal)
1In several patients (estimated number: 8–10), CSF specimen will be obtained under long-term natalizumab (i.e. baseline) and
after 24 weeks of fingolimod therapy and will immediately be analyzed by flow cytometry
2Patients with a history of uveitis or with diabetes mellitus must perform an ophthalmologic examination prior to the treatment start of fingolimod.
Ophthalmologic examination includes eye history and procedures necessary to assess macular edema (e.g. ophthalmoscopy). OCT is only done to confirm
macular edema
3Patients will be monitored on-site in the clinic for at least six hours after dose administration at First Dose Monitoring (FDM) visits (see Appendix 3 for details).
Pulse and blood pressure will be obtained three times for pre-dose assessment. The monitoring includes a 12-lead ECG prior and 6 hours after the first dose, as
well as blood pressure and heart rate measurement every hour
after the first dose
4Window for MRI is +/− 7 days
5If a patient discontinues study treatment early due to relapse and last MRI was > 10 days from relapse confirmation, an MRI should be performed, if possible,
prior to initiation of corticosteroid treatment
6MSFC at Screening (V1) should be taken as rehearsal
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evaluated by multi-color flow cytometry; here, we will
address effects on T helper cell subsets (i.e. Th1, Th17,
Treg subpopulations) CD8 T cells, B cell subpopulations,
monocytes, dendritic cells, and NK cells. Moreover, the
influence on CD62L expression will be determined. The
aim of this exploratory objective is to search for poten-
tial immunological alterations in the course of treatment
switching, which might affect the quality of the immune
response and hence indicate an impairment of cellular
immune functions e.g. during infections.
CSF analysis In some participants, CSF will be analyzed
at baseline (i.e. under natalizumab treatment) and after
24 weeks of fingolimod treatment. Immune cell subset
composition within the CSF will be assessed. Due to the
limited amount of material, we will focus on CD4+ and
CD8+ T cells, B cells, NK cells and Th17 cells. This ana-
lysis aims to determine changes in the immune surveil-
lance capacity in the course of switching from natalizumab
to fingolimod.
DTI imaging With regard to radiological disease activ-
ity, all patients will be longitudinally screened for “silent”
disease activity as detected by quantitative DTI imaging
in order to search for radiological signs of disease
exacerbation related to natalizumab treatment cessation
that escapes detection by conventional radiological read
outs. Quantitative DTI parameters (mean diffusivity, ra-
dial diffusivity, axial diffusivity, linear diffusivity, planar
diffusivity, and spherical diffusivity in selected regions of
interest) will be compared longitudinally and with data
from an age and gender matched normal control cohort
of 30 healthy control subjects.
Clinical parameters Clinical parameters that will be
determined during the whole study are number of re-
lapses, defined as new development, aggravation or re-
occurrence of a neurological abnormality compatible
with MS that lasts for at least 24 h, does not occur in
the context of fever or infections and that is separated
from a preceding clinical event by at least 30 days.
Moreover, clinical disease severity will be assessed by
EDSS [26] at each visit. These data serve as parameters
for determination of clinical treatment responses and
changes in clinical disease activity during the trial. Al-
though due to the limited number of participants these
parameters do not represent endpoints on their own,
they will be used for correlation with immunological as
well as radiological parameters in order to investigate a
potential relationship between clinical response and im-
munological alterations.
Sample size
The sample size calculation is based on the two primary
endpoints CD49d expression over time and changes in
the migratory capacity in an in-vitro model of the BBB.
A change of 16 units with a standard deviation of 20
units in CD49d expression from baseline to the end of
the washout period is deemed clinically relevant. A num-
ber of 15 patients results in a power of 82 % for a two-
sided Student’s t-test for matched pairs with a significance
level of 5 %. A sample size of 15 patients also enables to
detect a change in the migratory capacity from baseline to
the end of the washout period of 4.6 % with a standard
deviation of 5.9 % using a power of 80 % with a two-
sided Student’s t-test for matched pairs with a signifi-
cance level of 5 %.
Statistical methods
Statistical analyses will be performed according to the
principles of the ICH guideline E9 using standard statis-
tical software. Endpoints will be evaluated for the full
analysis set as well as for the per protocol set that contains
patients that were treated at least once with fingolimod
and have valid data for at least one visit during the two
year treatment phase. Data on safety will be analyzed de-
scriptively including all patients that received at least one
dose of the investigational drugs (safety population).
The two primary endpoints will be tested hierarchic-
ally using the per-protocol set and student’s t-test for
matched pairs. Other endpoints will be analyzed descrip-
tively using summary measures such as mean and stand-
ard deviation, median and quartiles, or frequency and
percent, as appropriate. To assess the difference of
measurements between two different time points, statis-
tical tests appropriate to the statistical distribution of the
particular endpoint will be used (Student’s t-test for
paired samples, Wilcoxon signed-rank test, Sign-Test).
For comparison of more than two successive measure-
ments, methods accounting for intra-individual correl-
ation will be used (e.g. Linear Mixed Models). Since the
study is regarded as an exploratory study (hypotheses
generating, not confirmatory), p-values will be inter-
preted accordingly.
A comparison with two adequate historical control
groups (healthy volunteers, n = 20, treatment naïve MS
Table 3 Immunological Assays
Biomaterial
Assay PBMC1 PB Immune
cells2
CSF2
Flow cytometric assessment of CD49d
and CD62L expression
X
In vitro transmigration across BBB X
VZV-specific T-cell response X
Immune phenotyping via flow cytometry X X X
1purified via density gradient centrifugation and cryo-preserved
2freshly obtained, treated with erythrocyte-lysis buffer
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patients, n = 20), for which data has been collected in
previous studies, will be carried out descriptively.
Discussion
The risk of developing PML as a consequence of estab-
lished treatment with natalizumab restricts its long-term
use despite high efficacy. However, natalizumab treat-
ment interruption has been shown to be associated with
an increased risk of disease exacerbation [9]. Hence,
there is a clear need of treatment regimes that allow for
satisfactory disease control after natalizumab treatment
cessation without an increased risk of severe side effects
due to compromised immune surveillance, such as PML
and other infections. Based on the available efficacy data,
one compound that seems suitable for treatment of active
RRMS after natalizumab discontinuation is fingolimod.
Hence, it is important to understand the consequences of
switching immune-modulatory treatment from natalizu-
mab to fingolimod both in terms of disease control and in
terms of consequences for cellular immune responses.
Several studies have already been dealing with the
identification of an optimal wash-out interval before post-
natalizumab treatment initiation: In this regard, it is now
believed that a wash-out interval beyond 12 weeks will re-
sult in a rebound of disease activity; therefore, such a long
treatment interruption is not recommended [33–35]. This
is also supported by data from a multi-center double-
blinded clinical trial performed by Novartis (ToFingo),
where three cohorts of patients were switched from natali-
zumab to fingolimod after a wash-out period of either
8 weeks, 12 weeks, or 16 weeks and disease activity was
subsequently monitored. Although this study was prema-
turely stopped, the data available on 142 patients demon-
strate that the 8-week wash-out group exhibited the least
amount of clinical disease activity and the smallest change
in T2 volume throughout the study (presented at
ECTRIMS 2013, abstracts 167 and 179).
On the other hand, a limited wash-out period might
be associated with safety issues due to potential synergis-
tic effects of both drugs on immune functions which
might hamper immune responses e.g. in the context of
infections. After 4 weeks of natalizumab treatment ces-
sation, antibody concentration in serum is still detect-
able [36] and even 8 weeks after stopping treatment with
natalizumab, saturation on the surface of circulating im-
mune cells is 70-79 % (on CD4+ T cells) [12], a value
which is hardly lower than the expected 80 % during
continuous therapy [37]. Saturation only begins to drop
significantly after 10 or more weeks. Therefore, fingoli-
mod treatment initiation after only 4 weeks would result
in sustained parallel exposure to natalizumab and fingo-
limod and we decided on a compromise between clinical
efficacy and biological response: a wash-out period of
8 weeks.
Concerning the study duration, we decided to monitor
patients for 6 months under fingolimod treatment, as it
has been suggested that a potential rebound of disease
activity upon switching will occur most likely 1–3 months
after fingolimod treatment onset. A follow-up of 6 months
after fingolimod treatment initiation is therefore regarded
as sufficient to detect potential disease exacerbation due
to switching.
Potential additive effects of natalizumab and fingoli-
mod on immune function have not been evaluated so
far. With regard to natalizumab, it is interesting to note
that the overall immune response is not affected even
under long-term exposure, and the risk of general infec-
tions is not enhanced. In contrast, there is a selectively
increased risk for PML, which is caused by reactivation
of a latent JC virus infection [38]. The underlying reason
for this selective deficit in immune surveillance with
regard to JC-virus under long-term natalizumab is still
unsolved. One possible explanation is that immune sur-
veillance of the CNS is impaired due to an unselective
interference with lymphocyte trafficking at the blood–
brain-barrier. Hence, latent local infections cannot be suf-
ficiently controlled any more. In favor of this hypothesis,
it has been demonstrated that the CD4+/CD8+ T-cell ra-
tio is selectively reduced in the cerebrospinal fluid (CSF)
but in not the peripheral blood of natalizumab patients
(i.e. 0,5 under natalizumab vs 3,7 in untreated MS patients
[13]. Interestingly, a similarly reduced CD4+/CD8+ T-cell
ratio has also been described in the CSF of HIV-infected
patients (i.e. ratio of 0.5), and the risk for an opportunistic
PML in HIV infected individuals is a well-known compli-
cation of chronic HIV-infection. Moreover, PML has been
observed in the context of other immune-suppressive
conditions such as idiopathic lymphopenia, hematologic
malignancies, after bone-marrow transplantation and
upon use of different biologicals such as efalizumab and
alemtuzumab, thus linking PML occurrence to either
CNS-local (i.e. under natalizumab) or systemic defects
in immune surveillance [38].
So far, only one case of PML in a fingolimod–treated
MS patient who did not receive natalizumab before has
been reported (Novartis). With regard to now approxi-
mately 172.500 patient-years of exposure, so far there is
no increased risk of PML under fingolimod. However, it
has to be taken into account that a few cases of PML
under fingolimod after switching from natalizumab have
been described; so far, it is not clear whether this is due to
“carry-over” PML, i.e. asymptomatic PML, which already
started under natalizumab, or whether the gradual use of
fingolimod after natalizumab has an impact on disease oc-
currence [22–24]. Moreover, fingolimod seems to harbor
an increased risk for herpes virus reactivations, and a few
cases of severe and atypical herpes virus infections have
been described so far [21].
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In light of these findings, we here present a study de-
sign that will contribute to our understanding of changes
in disease severity and alterations in immune functions
upon switching from natalizumab to fingolimod in pa-
tients suffering from active relapsing-remitting multiple
sclerosis. In contrast to most of the published reports on
clinical outcomes of patient cohorts upon switching,
where quality of data analysis is limited due to the obser-
vational nature of data collection and the fact that the
wash-out period was not standardized, we decided for a
highly controlled study design that will generate high-
quality data to allow proper assessment of disease activ-
ity in terms of MRI-related changes as well as clinical
relapse rate in our cohort. In light of the available infor-
mation regarding the wash-out interval, we decided to
focus on an interval of 8 weeks for all patients rather
than comparing different wash-out intervals. Concerning
the high frequency of patient visits implemented in the
study protocol, we aim to collect high-frequent MRI
data as well as clinical information allowing for a de-
tailed analysis of subtle changes in disease activity over
time in each individual.
A detailed and high-frequent analysis of immune func-
tions over time as implemented in our protocol has not
yet been performed before in a comparable patient co-
hort. We believe that it is pivotal to increase our under-
standing of potential additive effects of these two drugs
on immune surveillance, particular with regard to immune
cell trafficking and cellular anti-viral immune responses.
Based on our previous experience with monitoring of im-
mune functions under long-term immune-modulatory
treatment with natalizumab and fingolimod [6, 39], we de-
signed several assays to evaluate changes in immune func-
tions over time during treatment switch. In particular, we
will here focus on changes in the expression of molecules
involved in immune cell adhesion and migration, i.e.
CD49d and CD62L, as well as changes in the migratory
capacity of peripheral immune cells, representing the two
co-primary endpoints of our study. Reduced CD49d ex-
pression is a well-known effect of natalizumab treatment,
and it has already been proposed that high-frequent meas-
urement of CD49d levels in patients over time might help
for individual dose adjustments [12]. Hence, restored
CD49d expression on peripheral immune cells might
serve a reliable parameter indicating disappearance of
natalizumab-related pharmacodynamic changes. On the
other hand, long-term natalizumab treatment alters
CD62L levels on peripheral immune cells, and further
decreased CD62L levels on immune cells from long-
term natalizumab-treated patients have been identified
as potential risk factor for developing PML later on [6].
We therefore want to assess potential changes in
CD62L expression over time during switching as this
has not been evaluated before. Given the fact that both
drugs interfere with immune cell trafficking, and dis-
tinct effects on immune cell subset migration across pri-
mary human brain endothelial cells by both drugs have
been described [27, 39], we want to assess whether we
might observe any changes in the migratory capacity of
different immune cell subpopulations during switching.
It is conceivable that despite a wash-out interval of
8 weeks there still might occur additive effects of both
drugs on immune cell trafficking that might indicate po-
tential safety issues with regard to local immune surveil-
lance within the CNS. Moreover, we will perform CSF
analysis by flow cytometry in individual study partici-
pants first at the end of natalizumab treatment and after
24 weeks of fingolimod treatment in order to assess
potential changes in the CD4+/CD8+ T-cell ratio and
immune cell activation status (i.e. level of HLA-DR
expression on immune cells). We will assess whether po-
tential natalizumab-induced changes in the CD4+/CD8+
T-cell ratio might recover upon switching to fingolimod.
Finally, we will evaluate functional changes in cellular
anti-viral responses against the herpes viruses CMV and
VZV over time during switching. Recent observational
data report an increased risk of herpes virus reactivation
under fingolimod [20, 21]. It is unclear, however, whether
preceding treatment with natalizumab might further im-
pact cellular immune responses against these viruses.
We are fully aware that the limited patient number
will prevent any definitive statements with regard to the
efficacy of fingolimod therapy after long-term natalizu-
mab treatment; however, this is not the scope of our
study. Instead we want to provide an in-depth analysis
of MRI data focusing on clinically silent disease activity
in order to better understand the kinetics of potential
disease exacerbation during switching and hence allow
for subsequent re-adaptation of the current treatment
paradigm especially with regard to the wash-out interval
later on. Moreover, we want to provide a data set that
allows for detection of changes in immune functions
during switching in order to further understand the phar-
macodynamic effects of both drugs and their successive
usage on key immune functions such as migration, im-
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